Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models.
Omnia Salah HeikalPatrick F van RheenenDaan J TouwJos G W KosterinkMarina MaurerJeroen V KoomenPierre ChellePaola MianPublished in: British journal of clinical pharmacology (2024)
The model by Vande Casteele et al. displayed superior performance in initial evaluations but had a high error in estimating next IFX levels and can only be used in practice to predict induction levels.